| Identification | More | [Name]
Torcetrapib | [CAS]
262352-17-0 | [Synonyms]
TORCETRAPIB-D3
(2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
Torcetrapib | [Molecular Formula]
C26H22D3F9N2O4 | [MDL Number]
MFCD08063631 | [Molecular Weight]
603.49 | [MOL File]
262352-17-0.mol |
| Chemical Properties | Back Directory | [Melting point ]
54-58°C | [Boiling point ]
504.8±50.0 °C(Predicted) | [density ]
1.42 | [storage temp. ]
Store at RT | [solubility ]
DMSO: >5mg/mL | [form ]
powder | [pka]
-1.87±0.40(Predicted) | [color ]
white | [optical activity]
[α]/D >-70° | [InChIKey]
CMSGWTNRGKRWGS-NQIIRXRSSA-N | [SMILES]
N1(C(OCC)=O)C2=C(C=C(C(F)(F)F)C=C2)[C@@H](N(CC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)C(OC)=O)C[C@H]1CC | [CAS DataBase Reference]
262352-17-0(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Low Melting Solid | [Uses]
Cholesteryl ester transfer protein (CETP) inhibitor. Antilipemic; antiatherosclerotic. | [Definition]
ChEBI: Torcetrapib is a member of quinolines, a carbamate ester and a member of (trifluoromethyl)benzenes. It has a role as an anticholesteremic drug and a CETP inhibitor. | [Biological Activity]
torcetrapib is a cetp inhibitor with ic50 of 37 nm, elevates hdl-c and reduces nonhdl-c in plasma. inhibition of cholesteryl ester transfer protein (cetp) has been shown to have a substantial effect on plasma lipoprotein levels. | [in vitro]
torcetrapib dose-dependently increases aldosterone release from h295r cells after either 24 or 48 h of treatment, this effect is mediated by calcium channel as calcium channel blockers completely blocks torcetrapib-induced corticoid release and calcium increase. torcetrapib (1 μm) significantly increases the expression of steroidogenic gene, cyp11b2 and cyp11b1, in h295r cell lines [1]. | [in vivo]
researchers tested torcetrapib in rabbits fed an atherogenic diet at a dose sufficient to increase hdl-c by at least 3-fold. cetp activity was inhibited by 70–80% throughout the study. non-hdl-c increased in both groups, but there was no difference apparent by the study’s end [2]. | [storage]
Store at -20°C | [References]
[1] hu x, dietz jd, xia c, knight dr, loging wt, smith ah, yuan h, perry da, keiser j. torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. endocrinology. 2009;150(5):2211-9.
[2] morehouse la, sugarman ed, bourassa pa, sand tm, zimetti f, gao f, rothblat gh, milici aj. inhibition of cetp activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in new zealand white rabbits. j lipid res. 2007;48(6):1263-72.
[3] barter pj, caulfield m, eriksson m, grundy sm, kastelein jj, komajda m, lopez-sendon j, mosca l, tardif jc, waters dd, shear cl, revkin jh, buhr ka, fisher mr, tall ar, brewer b; illuminate investigators. effects of torcetrapib in patients at high risk for coronary events. n engl j med. 2007;357(21):2109-22. |
|
|